Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 14
---
 "MDCXW," respectively. The warrants offered hereby will not be listed on any U.S. securities exchange.                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dividend policy                 | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. |
| Risk factors                    | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares and warrants.                                                                                                                                                                                                                                                                                                                                                                                                               |

<div align='center'>6</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Except as otherwise noted, all information contained in this prospectus assumes:

The number of common shares that will be outstanding after this offering is based on 13,428,561 common shares outstanding as of April 15, 2025.

<div align='center'>7</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus.

We have derived the selected consolidated statement of operations for the years ended December 31, 2024 and 2023 and the selected consolidated balance sheet information as of December 31, 2024 and 2023 from our audited consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance with GAAP and our consolidated financial statements are presented in U.S. dollars, except where indicated otherwise. Our historical results are not necessarily indicative of the results that should be expected in any future period.

<div align='center'>CONSOLIDATED STATEMENT OF OPERATIONS</